Breast cancer is the most common cancer in women globally, with hot flashes and night sweats being common side effects of adjuvant endocrine therapies used in treatment. Astellas Pharma has initiated the HIGHLIGHT 1™ Phase 3 study to evaluate fezolinetant, a nonhormonal compound, for treating moderate to severe vasomotor symptoms in women with breast cancer. The study aims to assess fezolinetant’s efficacy and safety in about 540 participants over 52 weeks. Fezolinetant works by blocking neurokinin B binding in the brain’s temperature control center to reduce the frequency and intensity of hot flashes and night sweats. There is no guarantee of regulatory approval for fezolinetant.
Source link
Astellas initiates Phase 3 Clinical Study of ▼Fenzolinetant for VMS in women with breast cancer receiving Adjuvant Endocrine Therapy
